CRDF · Cardiff Oncology, Inc.

Exercisable beginning on the later of (i) six months after issuance or (ii) the Authorized Share Increase Date (the "Initial Exercise Date"). "Authorized Share Increase Date" means the date on which an amendment to the Issuer's certificate of incorporation increasing the number of authorized shares of its common stock to an amount sufficient for the exercise in full of the Common Warrants is filed with and accepted by the State of Delaware, subject to approval of such amendment by its stockholders.

The term of exercise is equal to five and one-half years after the Initial Exercise Date.

Exercisable beginning on the later of (i) six months after issuance or (ii) the Authorized Share Increase Date (the "Initial Exercise Date"). "Authorized Share Increase Date" means the date on which an amendment to the Issuer's certificate of incorporation increasing the number of authorized shares of its common stock to an amount sufficient for the exercise in full of the Common Warrants is filed with and accepted by the State of Delaware, subject to approval of such amendment by its stockholders.

The term of exercise is equal to five and one-half years after the Initial Exercise Date.

100,000 vest on April 27, 2027 and 8,333 vest monthly for 36 months beginning on May 27, 2027

75,000 vest on April 14, 2027 and 6,250 vest monthly for 36 months thereafter

121,663 vest on April 6, 2027 and 10,139 vest monthly for 36 months thereafter.

121,663 vest on April 6, 2027 and 10,139 vest monthly for 36 months thereafter.

150,000 vest on March 31, 2027 and 12,500 vest monthly for 36 months thereafter

50,000 vest on February 13, 2027 and 4,166 vest monthly for 36 months thereafter.

25% of the shares subject to the option will vest on March 11, 2026 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the continued service of the reporting person.

25% of the shares subject to the option will vest on March 11, 2026 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the continued service of the reporting person.

25% of the shares subject to the option will vest on March 11, 2026 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the continued service of the reporting person.

25% of the shares subject to the option will vest on March 11, 2026 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the continued service of the reporting person.

25% of the shares subject to the option will vest on March 7, 2025 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the continued service of the reporting person.

25% of the shares subject to the option will vest on March 7, 2025 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the continued service of the reporting person.

25% of the shares subject to the option will vest on March 7, 2025 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the continued service of the reporting person.

25% of the shares subject to the option will vest on March 7, 2025 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the continued service of the reporting person.

The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.95 to $1.01. Full information regarding the number of shares purcahsed at each separate price can be furnished to the SEC staff upon request.